CNS & Neurological Disorders - Drug Targets

CNS & Neurological Disorders - Drug Targets is a peer-reviewed journal that covers the molecular targets behind disorders of the brain and the nervous system.《CNS & Neurological Disorders - Drug Targets》是一份同行评审期刊，覆盖脑与神经系统疾病背后的分子靶点。

It is published by Bentham Science and traces its line to a title launched in 2002, which took its present name in 2006.该刊由边沁科学出版社出版，其血脉可上溯到 2002 年创刊的一份刊物，2006 年启用现名。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3, and it stands in the second quartile of neurosciences and of pharmacology.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在神经科学类目与药理学类目均列第二区。

Scope

• The journal sets out to cover the medicinal chemistry of targets that sit behind a disorder of the central nervous system, and it takes work at that junction.该刊意在覆盖中枢神经系统疾病背后靶点的药物化学，收载处于这一交界处的工作。

• Pharmacology is a named subject, and the journal carries work on how a compound acts on a receptor or an enzyme in the nervous system.药理学是被点名的选题，该刊刊载化合物如何作用于神经系统受体或酶的工作。

• Molecular biology is part of the remit, and the journal admits work on how a target is expressed and how it is regulated.分子生物学属于收稿范围，该刊收载靶点如何表达、如何被调控的工作。

• Genomics is treated, and the journal carries work on how a variant shapes the risk of a neurological disorder.基因组学得到处理，该刊刊载变异如何塑造神经疾病风险的工作。

• Biochemistry is weighed alongside the rest, and the journal takes work on the reactions and the structures that underlie a target.生物化学与其余方向一并权衡，该刊收载作为靶点基础的化学反应与结构方面的工作。

• Disease specific proteins are named among the targets, and the journal carries work on a protein that marks a particular disorder.疾病特异性蛋白被列为靶点之一，该刊刊载标记某一特定疾病的蛋白方面的工作。

• Receptors are treated as a class of target, and the journal admits work on how a ligand is made to bind selectively.受体作为一类靶点得到处理，该刊收载如何使配体选择性结合的工作。

• Enzymes appear among the named targets, and the journal carries work on how an inhibitor is found and how it is made potent.酶出现在被点名的靶点之中，该刊刊载抑制剂如何被发现、如何变得强效的工作。

• Genes are treated as targets, and the journal takes work on how the expression of a nervous system gene is altered.基因作为靶点得到处理，该刊收载神经系统基因表达如何被改变的工作。

• Neurodegeneration is part of the remit, and work on targets tied to such conditions as Alzheimer disease and Parkinson disease is admitted.神经退行属于收稿范围，与阿尔茨海默病、帕金森病等相关的靶点工作受到收载。

• Psychiatric and pain conditions are named, and the journal carries work on the targets that bear on them.精神疾患与疼痛状况被点名，该刊刊载与之相关的靶点工作。

• Drug clinical trial studies are admitted, and the journal takes work that carries a target from the bench toward a patient.药物临床试验研究受到收载，该刊收载把靶点从实验台带向患者的工作。

• Original research, letters and reviews are all taken, and the journal sets out the structure each class should follow.原始研究、快报与综述均予收载，该刊列出各类别应遵循的结构。

• Thematic issues are a feature, and the journal gathers guest edited collections on a chosen topic from leaders in the field.专题期是其一特色，该刊就选定的题目汇集由领域领军人物客座主编的合集。

History

• The line began in 2002, when Current Drug Targets - CNS & Neurological Disorders was launched by the same publisher.该血脉始于 2002 年，同年一份名为（Current Drug Targets - CNS & Neurological Disorders）的刊物由同一出版方创办。

• That earlier title ran from volume 1, issue 1 in February 2002 to volume 4, issue 6 in December 2005.那更早的题名自 2002 年 2 月第 1 卷第 1 期，延续到 2005 年 12 月第 4 卷第 6 期。

• In 2006 the journal was renamed, and the volume number was carried straight on, so that the new name began at volume 5.2006 年该刊更名，卷号原样接续，新题名自第 5 卷开始。

• The pair of numbers changed with the name, and the current print and electronic editions use their own pair.刊号随题名一并更改，现行印本与电子版使用它们自己的一对号码。

• The journal is published by Bentham Science, a house based in Sharjah in the United Arab Emirates.该刊由边沁科学出版社出版，该社设于阿拉伯联合酋长国的沙迦。

• Twelve issues are gathered into a year in the present arrangement, and volume 25 runs through 2026.按现行安排该刊每年汇集十二期，2026 年出至第 25 卷。

• An earlier arrangement put out fewer numbers in a year, and a record of the title still carries the bimonthly rhythm of 2006.早先的安排每年期数较少，某条记录仍载着 2006 年的双月节奏。

• The impact figure has moved with the field, standing at 4.388 for 2021 and reaching 3.3 in the 2025 edition.影响因子随领域而波动，2021 年为 4.388，2025 年版为 3.3。

• A quarter of the content is given to guest edited thematic issues, and the journal commissions them from leaders in the field.约四分之一的篇幅给到客座主编的专题期，该刊向领域领军人物约请此类合集。

• The publisher sells open access as an option, and an accepted paper may be made free to read on payment of a charge.出版方把开放获取作为一项可选，被录用的论文可在缴费后免费阅读。

• The journal is indexed in the science citation index expanded, and it is carried in MEDLINE and in PubMed.该刊被科学引文索引扩展版收录，并被 MEDLINE 与 PubMed 收录。

• It is also carried in Scopus and in the abstracting services for neuroscience and for pharmacology.该刊亦被 Scopus 以及神经科学与药理学的文摘服务收录。

Editors

• Edoardo Spina of the University of Messina in Italy is editor-in-chief, and his own field is clinical neuropsychopharmacology.意大利墨西拿大学的（Edoardo Spina）担任主编，其本人领域为临床神经精神药理学。

• Three co-editors-in-chief share the office, Cristoforo Comi of the University of Piemonte Orientale in Italy, and Sergio Machado and Fabricia Petronilho in Brazil.另有三位共同主编分担此职，即意大利东皮埃蒙特大学的（Cristoforo Comi），以及巴西的（Sergio Machado）与（Fabricia Petronilho）。

• Regional editors are named for each part of the world, and the journal lists one for central America and others for further regions.世界各地区各有区域编辑，该刊为中美洲列出一位，并为更远的地区另列数位。

• A large editorial board advises on content, and the journal draws its members from universities and research institutes across several continents.一个规模不小的编委会为内容提供建议，该刊的成员来自数个大洲的大学与研究机构。

• Manuscripts are submitted through the publisher's system, and the journal sets out the classes of contribution it takes.稿件通过出版方的系统投递，该刊列明所收稿件的类别。

• A thematic issue is proposed to the publisher and to the editors, and a guest editor then assembles the collection.专题期须向出版方与编辑提案，再由一位客座主编汇集合集。

• A manuscript judged to fit another title may be offered a transfer, and the editorial team helps the author move it.被判断更适合另一刊物的稿件可获转投之请，编辑团队协助作者将其转出。

• The journal states its ethical requirements in full, and authors must declare any competing interest.该刊完整说明其伦理要求，作者必须声明任何利益冲突。

• The publisher keeps to the codes of conduct for publication ethics, and the journal says it complies with them.出版方遵守出版伦理的行为准则，该刊称其予以遵循。

• Where a claim rests on new compound data, the journal asks that the supporting characterisation be given.论断若依赖新的化合物数据，该刊要求给出支撑性的表征。

• The journal is read by medicinal chemists and by neuroscientists, by pharmacologists and by clinicians, and it writes for all of them.该刊的读者既有药物化学家与神经科学家，也有药理学家与临床医生，它为这几类人写作。

• Work that links a molecular finding to a disorder is given room, and the journal asks what the link promises for treatment.把分子发现与疾病相连的工作有篇幅可用，该刊追问这一联系对治疗寄予何种希望。

• Studies that report a negative result are taken, since a target that proves unworkable is worth recording.报告阴性结果的研究也在收载之列，因为被证明行不通的靶点同样值得记录。

• Work on blood brain barrier penetration is treated, and the journal carries papers on how a compound is made able to reach the brain.血脑屏障穿透方面的工作得到处理，该刊刊载化合物如何被做得能抵达脑部。

• Biomarkers are named among the subjects, and the journal takes work on how a marker tracks the course of a disorder.生物标志物列于选题之中，该刊收载标志物如何追踪疾病进程的工作。

• Neuroinflammation appears among the subjects, and the journal carries work on the targets that govern it.神经炎症列于选题之中，该刊刊载支配它的靶点方面的工作。

• The journal keeps its reviews distinct from its original reports, and a reader can tell from the rubric which is which.该刊把综述与原始报告区分开来，读者可从栏目看出何者为何者。

• Where a claim rests on an animal model, the journal asks that the model be described in full so that another laboratory can repeat the work.论断若依赖动物模型，该刊要求完整描述该模型，使另一实验室可以重复这项工作。